Factors Affecting the Outcome of the Operable Subtype Luminal B Breast Cancer Treatment

Authors

  • Meri Novita School of Medicine, Universitas Andalas, Padang, West Sumatera
  • Wisma Arif Harahap School of Medicine, Universitas Andalas, Padang, West Sumatera
  • Rahmat Taufik School of Medicine, Universitas Andalas, Padang, West Sumatera

DOI:

https://doi.org/10.55324/ijoms.v2i3.308

Keywords:

operable subtype luminal B, breast cancer, treatment

Abstract

Breast cancer is a condition of uncontrolled breast cell proliferation that most frequently develops from the ductal epithelial cells (85%) or lobules (15%) of the breast glands. Poor prognoses for patients can result from cancer's extensive organ metastasis, now the second largest cause of cancer death in women. This study aims to identify the variables that affect how well patients with the operable breast cancer subtype Luminal B respond to treatment at RSUP DR M Djamil Padang. This research used a cross-sectional methodology with a retrospective study approach to identify characteristics that affect the treatment outcome for operable breast cancer subtype luminal B at RSUP DR. M. Djamil Padang. From August to November 2022, the study was carried out in the Oncology Surgery Division of RSUP DR. M. Djamil Padang. With HER2 being the main component, multivariate analysis revealed that HER2 and the kind of therapy were significantly connected with the treatment outcome for cancer patients.

References

Albain, K., Anderson, S., Arriagada, R., Barlow, W., Bergh, J., Bliss, J., Buyse, M., Cameron, D., Carrasco, E., Clarke, M., Correa, C., Coates, A., Collins, R., Costantino, J., Cutter, D., Cuzick, J., Darby, S., Davidson, N., Davies, C., … Wood, W. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet, 379(9814). https://doi.org/10.1016/S0140-6736(11)61625-5

Center for Disease Control and Prevention. (2019). Basic information about breast cancer. Center for Disease Control and Prevention.

Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., Perou, C. M., Ellis, M. J., & Nielsen, T. O. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute, 101(10). https://doi.org/10.1093/jnci/djp082

Chen, B. F., Tsai, Y. F., Huang, C. C., Hsu, C. Y., Lien, P. J., Wang, Y. L., Lin, Y. S., Feng, C. J., King, K. L., Chiu, J. H., Chau, G. Y., & Tseng, L. M. (2022). Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan. Journal of the Chinese Medical Association?: JCMA, 85(2). https://doi.org/10.1097/JCMA.0000000000000632

Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., & Shi, B. (2015). Breast cancer intrinsic subtype classification, clinical use and future trends. In American Journal of Cancer Research (Vol. 5, Issue 10).

Ehinger, A., Malmström, P., Bendahl, P. O., Elston, C. W., Falck, A. K., Forsare, C., Grabau, D., Rydén, L., Stål, O., & Fernö, M. (2017). Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncologica, 56(1). https://doi.org/10.1080/0284186X.2016.1237778

Gómez-Acebo, I., Dierssen-Sotos, T., Palazuelos-Calderón, C., Pérez-Gómez, B., Amiano, P., Guevara, M., Molina, A. J., Domingo, L., Fernández-Ortiz, M., Moreno, V., Alguacil, J., Fernández-Tardón, G., Ibáñez, J., Marcos-Gragera, R., Diaz-Santos, M., Alonso, M. H., Alonso-Molero, J., Castaño-Vinyals, G., Palomo, A. G., … Llorca, J. (2020). Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Research and Treatment, 181(3). https://doi.org/10.1007/s10549-020-05600-x

Gradishar, W. J. (2012). Taxanes for the treatment of metastatic breast cancer. In Breast Cancer: Basic and Clinical Research (Vol. 6, Issue 1). https://doi.org/10.4137/BCBCR.S8205

Ho, P. J., Ow, S. G. W., Sim, Y., Liu, J., Lim, S. H., Tan, E. Y., Tan, S. M., Lee, S. C., Tan, V. K. M., Yap, Y. S., Chay, W. Y., Tan, B. K. T., Wong, F. Y., Li, J., & Hartman, M. (2020). Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-58007-5

Indonesia’s Ministry of Health. (2012). Profil data kesehatan Indonesia tahun 2011.

Karakolevska-Ilova, M., Zdravkovska, M., Jasar, D., Petrusevska, G., & Simeonovska-Joveva, E. (2021). Can estrogen receptor, progesterone receptor, and proliferative index be considered as isolated prognostic factors of overall survival in early luminal breast cancer? Open Access Macedonian Journal of Medical Sciences, 9. https://doi.org/10.3889/oamjms.2021.6102

Kementrian Kesehatan RI. (2016). Profil kesehatan Indonesia tahun 2015. Kementrian Kesehatan RI.

Kim, K. H., Chae, B. J., Song, B. J., & Jung, S. S. (2013). Ki-67 and p53 as prognostic factors for luminal type breast cancer. Journal of Breast Disease, 1(1). https://doi.org/10.14449/jbd.2013.1.3

Kondov, B., Milenkovikj, Z., Kondov, G., Petrushevska, G., Basheska, N., Bogdanovska-Todorovska, M., Tolevska, N., & Ivkovski, L. (2018). Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. Open Access Macedonian Journal of Medical Sciences, 6(6). https://doi.org/10.3889/oamjms.2018.231

Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002). The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. Journal of Clinical Oncology, 20(9). https://doi.org/10.1200/JCO.2002.09.023

Li, Z. H., Hu, P. H., Tu, J. H., & Yu, N. S. (2016). Luminal B breast cancer: Patterns of recurrence and clinical outcome. Oncotarget, 7(40). https://doi.org/10.18632/oncotarget.11344

Lian, W., Fu, F., Lin, Y., Lu, M., Chen, B., Yang, P., Zeng, B., Huang, M., & Wang, C. (2017). The impact of young age for prognosis by subtype in women with early breast cancer. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-10414-x

Liu, Z., Sahli, Z., Wang, Y., Wolff, A. C., Cope, L. M., & Umbricht, C. B. (2018). Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. Breast Cancer Research and Treatment, 172(3). https://doi.org/10.1007/s10549-018-4950-4

Mohammed, A. A. (2021). Prognostic parameter differences in breast cancer patients between luminal A and luminal B types after application of the new classification according to Ki67 score. International Journal of Surgery Open, 34. https://doi.org/10.1016/j.ijso.2021.100357

Pangribowo, S. (2019). Beban Kanker di Indonesia. In Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI. Pusat Data dan Informasi Kesehatan Kementerian Kesehatan RI.

Paramita, S., Raharjo, E. N., Niasari, M., Azizah, F., & Hanifah, N. A. (2019). Luminal B is the most common intrinsic molecular subtypes of invasive ductal breast carcinoma patients in East Kalimantan, Indonesia. Asian Pacific Journal of Cancer Prevention, 20(8). https://doi.org/10.31557/APJCP.2019.20.8.2247

Pellegrino, B., Hlavata, Z., Migali, C., de Silva, P., Aiello, M., Willard-Gallo, K., Musolino, A., & Solinas, C. (2021). Luminal breast cancer: Risk of recurrence and tumor-associated immune suppression. In Molecular Diagnosis and Therapy (Vol. 25, Issue 4). https://doi.org/10.1007/s40291-021-00525-7

Rabinovich, I., de Noronha, L., Sebastião, A. P. M., Lima, R. S., Urban, C. A., Schunemann, E., Elífio-Esposito, S., Spautz, C. C., & Moreno-Amaral, A. N. (2018). HER2-expressing breast tumors are associated with breast cancer stem-cell phenotype CD44 + /CD24 -. Jornal Brasileiro de Patologia e Medicina Laboratorial, 54(5). https://doi.org/10.5935/1676-2444.20180052

Rahmatya, A., Khambri, D., & Mulyani, H. (2015). Hubungan usia dengan gambaran klinikopatologi kanker payudara di Bagian Bedah RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas, 4(2).

Rajc, J., Fröhlich, I., Mr?ela, M., Tomaš, I., & Flam, J. (2018). Prognostic impact of low estrogen and progesterone positivity in luminal b (HER2 negative) breast cancer. Acta Clinica Croatica, 57(3). https://doi.org/10.20471/acc.2018.57.03.04

Serrano-Gomez, S. J., Sanabria-Salas, M. C., Hernández-Suarez, G., García, O., Silva, C., Romero, A., Mejía, J. C., Miele, L., Fejerman, L., & Zabaleta, J. (2016). High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis, 37(7). https://doi.org/10.1093/carcin/bgw043

Tang, L. C., Jin, X., Yang, H. Y., He, M., Chang, H., Shao, Z. M., & Di, G. H. (2015). Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China. BMC Cancer, 15(1). https://doi.org/10.1186/s12885-015-1207-z

Thangarajah, F., Enninga, I., Malter, W., Hamacher, S., Markiefka, B., Richters, L., Krämer, S., Mallmann, P., & Kirn, V. (2017). A retrospective analysis of Ki-67 index and its prognostic significance in over 800 primary breast cancer cases. Anticancer Research, 37(4). https://doi.org/10.21873/anticanres.11536

Utsumi, T., Kobayashi, N., Hikichi, M., Ushimado, K., & Kuroda, M. (2021). Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and-negative subtypes. Fujita Medical Journal, 7(4), 130–135.

Wilson, B. E., Desnoyers, A., Al-Showbaki, L., Nadler, M. B., & Amir, E. (2022). A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. Scientific Reports, 12(1), 1–8.

Downloads

Published

2022-12-15

Issue

Vol. 2 No. 3 (2022): Indonesian Journal of Multidisciplinary Science

Section

Articles

License

Copyright (c) 2022 Meri Novita, Wisma Arif Harahap, Rahmat Taufik

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC-BY-SA). that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.